Alkermes plc. Depreciation
Alkermes plc. (ALKS) reported Depreciation of $31.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-02-25
- Alkermes plc. depreciation for the quarter ending 2012-03-31 was -$4.75M, a 290.80% decline year-over-year.
- Alkermes plc. depreciation for the quarter ending 2011-12-31 was $20.87M, a 871.79% increase year-over-year.
- Alkermes plc. depreciation for the quarter ending 2011-03-31 was $2.49M.
- Alkermes plc. depreciation for the quarter ending 2010-12-31 was $2.15M.
- Alkermes plc. depreciation for fiscal 2025 was $31.10M, a 13.50% increase from fiscal 2024.
- Alkermes plc. depreciation for fiscal 2024 was $27.40M, a 6.61% increase from fiscal 2023.
- Alkermes plc. depreciation for fiscal 2023 was $25.70M, a 2.28% decline from fiscal 2022.
- Alkermes plc. depreciation for fiscal 2022 was $26.30M, a 12.88% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $31.10M 10-K · filed 2026-02-25 | ||||
| 2024-12-31 | $27.40M 10-K · filed 2026-02-25 | ||||
| 2023-12-31 | $25.70M 10-K · filed 2026-02-25 | ||||
| 2022-12-31 | $26.30M 10-K · filed 2025-02-12 | $41.70M 10-K · filed 2023-02-16 | |||
| 2021-12-31 | $23.30M 10-K · filed 2024-02-21 | $40.50M 10-K · filed 2022-02-16 | |||
| 2020-12-31 | $42.40M 10-K · filed 2023-02-16 | ||||
| 2019-12-31 | $40.10M 10-K · filed 2022-02-16 | ||||
| 2018-12-31 | $38.50M 10-K · filed 2021-02-11 | ||||
| 2017-12-31 | $36.50M 10-K · filed 2020-02-13 | ||||
| 2016-12-31 | $33.30M 10-K · filed 2019-02-15 | ||||
| 2015-12-31 | $27.90M 10-K · filed 2018-02-16 | ||||
| 2014-12-31 | $39.90M 10-K · filed 2017-02-17 | ||||
| 2013-12-31 | $32.30M 10-K · filed 2016-02-25 | ||||
| 2013-03-31 | $31.90M 10-K · filed 2015-02-24 | ||||
| 2012-03-31 | -$4.75M derived: 10-KT 12 month − 10-Q 9 month · filed 2014-02-27 | $16.12M derived: sum of 2 quarters · filed 2014-02-27 | $22.50M 10-KT · filed 2014-02-27 | ||
| 2011-12-31 | $20.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-02 | $27.25M 10-Q · filed 2012-02-02 | |||
| 2011-09-30 | $6.38M 10-Q · filed 2011-11-03 | ||||
| 2011-03-31 | $2.49M derived: 10-K 12 month − 10-Q 9 month · filed 2013-05-23 | $4.64M derived: sum of 2 quarters · filed 2013-05-23 | $8.70M 10-K · filed 2013-05-23 | $8.65M 10-K · filed 2012-05-18 | |
| 2010-12-31 | $2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-02 | $6.21M 10-Q · filed 2012-02-02 | |||
| 2010-09-30 | $4.06M 10-Q · filed 2011-11-03 | ||||
| 2010-03-31 | $25.03M 10-K · filed 2012-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |